Imatinib mesylate inhibits the growth of metastatic lung lesions in a patient with dcrmatofibrosarcoma protuberans

Department of Dermatology, Aichi Medical University, Koromo, Aichi, Japan
British Journal of Dermatology (Impact Factor: 4.28). 08/2004; 151(1):235-7. DOI: 10.1111/j.1365-2133.2004.06024.x
Source: PubMed
6 Reads
  • Source
    • "We identified 23 case reports [19,20,23-25,27,29-32,35,38,39,41,42,50-52], [55-59], 15 case series [16,26,33,34,36,37,45,47,53,60-65], 6 phase II studies [18,40,46,48,49] and 4 pediatric studies [28,43,44,54] where Imatinib was used for the treatment of patients with DFSP. These studies include a total of 199 patients. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Dermatofibrosarcoma Protuberans (DFSP) is a rare skin tumor, characterized by frequent local recurrence but is seldom metastatic. It is histologically characterized by storiform arrangement of spindle cells. Cytogenetically, most tumors are characterized by translocation 17:22 leading to overexpression of tyrosine kinase PDGFB which can be targeted with tyrosine kinase inhibitor, Imatinib. We describe the first case of unresectable pancreatic metastases from DFSP treated with neoadjuvant Imatinib and subsequently R0 metastectomy. Additionally, a comprehensive systematic review of DFSP pancreatic metastases and the current published data on the use of Imatinib in DFSP is summarized.
    08/2014; 4(1):8. DOI:10.1186/2045-3329-4-8
  • Source
    • "The formation of COL1A1-PDGFB fusion gene results in the constitutional upregulation of PDGFB expression, leading to continuous autocrine activation of PDGF receptor B (PDGFRB) which is a key pathogenetic factor [46]. Based on the inhibitory effects of Imatinib on DFSP cell growth in various in vitro and in vivo studies [47], initial case reports showed the benefit of Imatinib in metastatic and locally advanced DFSP [48, 49]. In the largest retrospective series, 10 patients with locally advanced or metastatic DFSP received Imatinib 800 mg daily. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Deregulated protein tyrosine kinase activity is central to the pathogenesis of human cancers. Targeted therapy in the form of selective tyrosine kinase inhibitors (TKIs) has transformed the approach to management of various cancers and represents a therapeutic breakthrough. Imatinib was one of the first cancer therapies to show the potential for such targeted action. Imatinib, an oral targeted therapy, inhibits tyrosine kinases specifically BCR-ABL, c-KIT, and PDGFRA. Apart from its remarkable success in CML and GIST, Imatinib benefits various other tumors caused by Imatinib-specific abnormalities of PDGFR and c-KIT. Imatinib has also been proven to be effective in steroid-refractory chronic graft-versus-host disease because of its anti-PDGFR action. This paper is a comprehensive review of the role of Imatinib in oncology.
    05/2014; 2014(2):357027. DOI:10.1155/2014/357027
  • Source
    • "Recently, the tyrosine kinase inhibitor Imatinib, was shown to induce regression of advanced DFSP when it is impossible to obtain surgical margins. According to a review of Mizutani et el., imatinib inhibited the growth of metastatic lung lesions in a patient with DFSP [13]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Dermatofibrosarcoma protuberans is an uncommon locally aggressive malignant neoplasm that most frequently appears in the trunk, followed by the extremities, head, and neck. But occurrence in the breast is extremely rare. We present a case of a 28-year-old woman, who had a history of trauma 5 years previously and excision 1 year before presentation at our clinic. We performed wide excision, together with microscopic and immunohistochemical analysis. No postoperative oncologic treatment was used and she remains disease-free 1 year after the surgery without any tumor recurrence. Here, we report a case of dermatofibrosarcoma protuberans in the female breast and present a detailed discussion of the diagnosis and treatment with reference to available literatures.
    World Journal of Surgical Oncology 01/2011; 9(1):1. DOI:10.1186/1477-7819-9-1 · 1.41 Impact Factor
Show more

Similar Publications